Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm Therapeutics (Nasdaq: KPTI) reported that it granted an aggregate of 1,850 restricted stock units (RSUs) to two newly hired employees as of August 31, 2026. The awards were issued under the company’s 2022 Inducement Stock Incentive Plan, as inducement grants in line with Nasdaq Listing Rule 5635(c)(4).
Each RSU award vests over three years, with 33 1/3% of the shares vesting on each anniversary of the grant date, subject to the employee’s continued service with Karyopharm.
Karyopharm Therapeutics (Nasdaq: KPTI) has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib to treat patients with myelofibrosis. The company has also requested Priority Review, which, if granted, could shorten FDA review to six months.
According to Karyopharm, the sNDA is supported in part by Phase 3 SENTRY trial data in JAK inhibitor–naïve myelofibrosis patients (N=353), using spleen volume reduction ≥35% at week 24 and symptom score change as co‑primary endpoints. The company expects to receive FDA filing acceptance and timeline information in Q4 2026 and plans to use long‑term overall survival data from SENTRY as confirmatory evidence for potential conversion from accelerated to traditional approval. Selinexor already holds U.S. and EU orphan designations for myelofibrosis and a U.S. Fast Track designation.
Karyopharm (Nasdaq: KPTI) reported second quarter 2026 total revenue of $33.4 million, including $30.8 million in U.S. XPOVIO net product revenue and $2.6 million in license and other revenue. Royalty revenue from partners rose to $2.5 million, reflecting broader ex-U.S. selinexor access.
The company remains on track to submit an August 2026 sNDA for selinexor plus ruxolitinib in myelofibrosis under the FDA Accelerated Approval pathway and plans to request Priority Review, supported by Phase 3 SENTRY data. Karyopharm reaffirmed 2026 total revenue guidance of $130–$150 million and U.S. XPOVIO guidance of $115–$130 million, while guiding 2026 R&D and SG&A expenses of $230–$245 million.
Second quarter 2026 loss from operations was $22.5 million, with a net loss of $67.0 million. Cash, cash equivalents, restricted cash and investments totaled $65.4 million at June 30, 2026. The company is actively evaluating financing and strategic alternatives amid a $15.8 million September 10, 2026 term-loan payment and a $10.0 million minimum liquidity covenant.
Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company’s management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to review results and provide company updates.
Investors can join the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start and requesting the Karyopharm Therapeutics call. A live webcast with slides will be available under “Events & Presentations” in the investor section of the company’s website, with an archived replay accessible about two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) reported an inducement equity grant made under Nasdaq Listing Rule 5635(c)(4). On July 31, 2026, the company granted 333 restricted stock units (RSUs) to a newly hired employee under its 2022 Inducement Stock Incentive Plan, as amended.
According to Karyopharm, the award is an inducement material to the employee’s acceptance of employment. The RSUs will vest over three years, with 33 1/3% of the shares vesting on each of the three consecutive anniversaries of the grant date, subject to the employee’s continued service with the company.
Karyopharm Therapeutics (Nasdaq: KPTI) plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA in August 2026 seeking accelerated approval of selinexor plus ruxolitinib for patients with myelofibrosis and will request Priority Review.
According to Karyopharm, recent FDA feedback indicated spleen volume reduction ≥35% (SVR35) appears to qualify as a reasonably likely surrogate endpoint to support use of the accelerated approval pathway. The sNDA will rely on Phase 3 SENTRY topline data, including statistically significant SVR35 at week 24, a promising overall survival signal, reductions in variant allele frequency, and the overall safety dataset. Long-term overall survival from the ongoing SENTRY trial, which randomized 353 JAK inhibitor–naïve myelofibrosis patients 2:1 to selinexor plus ruxolitinib versus placebo plus ruxolitinib, is planned to verify clinical benefit.
Karyopharm Therapeutics (Nasdaq: KPTI) reported topline Phase 3 results from the global XPORT-EC-042 trial evaluating once-weekly oral selinexor as maintenance monotherapy versus placebo in 257 adults with TP53 wild-type advanced or recurrent endometrial cancer.
The trial did not meet its primary endpoint of progression-free survival (PFS). In the modified intent-to-treat (mITT) population (n=236), median PFS was 12.75 months with selinexor versus 7.43 months with placebo (hazard ratio 0.76; 95% CI: 0.51–1.12; one-sided p=0.0791), corresponding to a 5.3‑month difference favoring selinexor. As of data cut-off, 106 PFS events had occurred in the mITT group.
The safety and tolerability of selinexor were consistent with its established profile, and no new safety signals were observed. Karyopharm will fully analyze the dataset, continue to follow patients for longer-term outcomes, and plans to present detailed results at a future medical meeting. The company said these findings do not affect ongoing selinexor trials in other indications and that it will reduce planned investment in endometrial cancer while prioritizing its myelofibrosis and multiple myeloma programs, with several myelofibrosis milestones expected in the second half of 2026.
Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,649 restricted stock units (RSUs) to four newly hired employees as of June 30, 2026. The awards were made under the 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Each RSU vests over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued service.
Karyopharm (Nasdaq: KPTI) will join a Cantor-hosted virtual fireside chat on June 8, 2026 at 12:00 p.m. ET. The webcast will feature senior management and Robert Coleman, MD, Principal Investigator of the Phase 3 XPORT-EC-042 endometrial cancer trial, with a replay available the same day.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that late‑breaking Phase 3 SENTRY data of selinexor plus ruxolitinib in myelofibrosis was selected as one of six top late‑breaking abstracts for oral presentation at EHA 2026.
The trial reports rapid, deep and sustained spleen volume reductions, similar symptom improvement, a promising overall survival signal, higher rates of ≥20% variant allele frequency reductions by week 24, and a manageable safety profile. A post‑hoc analysis of 24 Phase 1 patients suggests achieving SVR35 may predict overall survival. The data will be presented June 14, 2026, and a peer‑reviewed Phase 3 publication is available in the Journal of Clinical Oncology.